gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · NAMSHealthcarePharmaceuticals

NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)

$20.93+5.18%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$20.93▼ 42.70% in range
Nov 4, 2025Low $19.53 · High $41.45Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

NewAmsterdam Pharma Company N.V. closed at $20.93 on Nov 4, up 5.18%, 49.5% below its 52-week closing high. Volume of 1.9M shares was 1.29× its 20-day average (above normal).

Split-adjusted performance: -6.0% over one month, -32.5% over six months, -43.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $3.70M, down 80.7% from a year earlier, with a net margin of -1732.9%.

Short interest was 14.1M shares at the Oct 15 settlement, down 25.9% from the prior report (16.4% of float, 10.6 days to cover).

Market cap$2.50B119.5M shares
Revenue · quarter$3.7M−80.7% YoY
Diluted EPS$-0.52—
P/E · TTM—P/S 351.3×
Net margin-1,732.9%Gross 100.0%
Dividend yieldNone
52-week range19.53 – 41.45−49.5% from high
Volume1.9M1.29× 20-day avg
Volatility · 60d52.4%Annualised
Short % of float16.4%10.6 days to cover
Net cash$633.9MCash $633.9M
Next earnings—Not scheduled
Split-adjusted performance
1W −0.7%1M −6.0%3M −24.4%6M −32.5%YTD −40.3%1Y −43.4%3Y +191.9%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum42
Revenue growth15
Net margin15
Value (low P/E)—
Size84

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short14.1M−25.9% vs prior
Days to cover10.6Settled Oct 15
% of float16.4%
Short vol. 10d33.8%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
NAMSNewAmsterdam Pharma Company N.V$20.93+5.18%−32.5%−80.7%−1732.9%—$2.50B
PBHPrestige Consumer Healthcare$53.28+7.55%−1.9%+6.5%11.0%14.7$2.52BCompare
MBXMBX Biosciences$52.48−4.58%+63.4%———$2.53BCompare
RCUSArcus Biosciences$19.31+2.12%−25.7%−74.4%−222.0%—$2.46BCompare
XNCRXencor$35.03+14.33%+169.3%+17.5%−42.4%—$2.60BCompare
PVLAPalvella Therapeutics$162.28+6.11%+24.7%———$2.34BCompare
VERAVera Therapeutics$31.97+4.10%−12.6%———$2.30BCompare
IMNMImmunome$19.52−3.89%−16.1%−100.0%——$2.30BCompare
BHVNBiohaven$15.24−2.37%+51.8%———$2.30BCompare

News about NewAmsterdam Pharma Company N.V

All news →
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific SessionsGlobeNewswire Inc. · Jun 3, 2026▲ PositiveNewAmsterdam Pharma to Participate at Upcoming Investor Conferences in JuneGlobeNewswire Inc. · May 28, 2026▲ PositiveNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc. · May 1, 2026Neutral

Quick answers

What does NewAmsterdam Pharma Company N.V. do?
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
What is NAMS's market cap?
$2.50B, based on the Nov 4 close of $20.93.
Does NewAmsterdam Pharma Company N.V. pay a dividend?
No regular cash dividend has been paid in the last year.
How much of NAMS is sold short?
14.1M shares, 16.4% of float, as of Oct 15, 2026.
What sector is NAMS in?
Healthcare, in the Pharmaceuticals industry.

About NewAmsterdam Pharma Company N.V

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

HQ: Narrden, P7100 employeesListed Nov 23, 2022newamsterdampharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology